Inhibitory effects of lysophosphatidylcholine on the dopaminergic system

Neurochemical Research

Volumn 29, Issue 7, 2004, Pages 1333-1342

  Lee, Eun Sook Y ^a   Chen, Hongtao ^a   Shepherd, Kennie R ^a   Lamango, Nazarius S ^a   Soliman, Karam F A ^a   Charlton, Clivel G ^a,b  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Dopaminergic system; Methylation; MPTP; Parkinson's disease; S adenosylmethionine

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; LYSOPHOSPHATIDYLCHOLINE; S ADENOSYLMETHIONINE; DOPAMINE RECEPTOR BLOCKING AGENT; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; MALE; NEUROTRANSMISSION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; STATISTICAL SIGNIFICANCE; TURNOVER TIME; ANIMAL; CELL MEMBRANE; CORPUS STRIATUM; DRUG EFFECT; KINETICS; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALIA;

ANIMALS; CELL MEMBRANE; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; KINETICS; LYSOPHOSPHATIDYLCHOLINES; MALE; PHOSPHOLIPIDS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 3442896815     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NERE.0000026394.92363.ee     Document Type: Article

References (61)

1. Thies, F., Delachambre, M. C., Bentejac, M., Lagarde, M., Lecerf, J. 1992. Unsaturated fatty acids esterified in 2-acyl-1-lysophosphatidylcholine bound to albumin are more efficiently taken up by the young rat brain than the un-esterified form. J. Neurochem. 59: 1110-1116.
2. Zhu, K., Baudhuin, L. M., Hong, G., Williams, F. S., Cristina, K. L., Kabarowski, J. H., Witte, O. N., and Xu. Y. 2001. Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. J. Biol. Chem. 276: 41325-11335.
3. Oishi, K., Raynor, R. L., Charp, P. A., and Kuo, J. F. 1988. Regulation of protein kinase C by lysophospholipids. Potential role in signal transduction. J. Biol. Chem. 263:6865-6871.
4. Cox, D. A. and Cohen, M. L. 1996. Lysophosphatidylcholine stimulates phospholipase D in human coronary endothelial cells: Role of PKC. Am. J. Physiol. 271:H1706-H1710.
5. Gomez-Munoz, A., O'Brien, L., Hundal, R., and Steinbrecher, U. P. 1999. Lysophosphatidylcholine stimulates phospholipase D activity in mouse peritoneal macrophages. J. Lipid Res. 40:988-993.
6. Kume, N. and Gimbrone, M. A., Jr. 1994. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J. Clin. Invest. 93:907-911.
7. Sakai, M., Miyazaki, A., Hakamata, H., Sasaki, T., Yui, S., Yamazaki, M., Shichiri, M., and Horiuchi, S. 1994. Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J. Biol. Chem. 269:31430-31435.
8. Yuan, Y., Jackson, S. P., Newnham, H. H., Mitchell, C. A., and Salem, H. H. 1995. An essential role for lysophosphatidylcholine in the inhibition of platelet aggregation by secretory phospholipase A2. Blood 86:4166-4174.
9. Steinberg, D., Parthasathy, S., Carew, T. E., Khoo, J. C., and Witztum, J. L. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:915-924.
10. +-ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients. Diabetes 43: 915-919.
11. DaTorre, S. D., Creer, M. H., Pogwizd, S. M., and Corr, P. B. 1991. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J. Mol. Cell. Cardiol. 23:11-22.
12. Maksem, J., Jacobson, N., Neiderhiser, D. H. 1984. Lysophosphatidylcholine-induced gastric injury and ulceration in the guinea pig. Am. J. Pathol. 115:288-295.
13. 2 activity and plasma lysophosphatidylcholine levels in asthma and rhinitis and their relationship to airway sensitivity to histamine. Am. Rev. Respir. Dis. 142:157-161.
14. 2-treated pre-synaptic membranes in vitro. Biochem. J. 318: 981-987.
15. 2 from rat neuronal cells and its possible function in the regulation of catecholamine secretion. Biochem. J. 318:701-709.
16. Oliveira, C. R., Duarte, E. P., and Carvalho, A. P. 1984. Effect of phospholipase digestion and lysophosphatidylcholine on dopamine receptor binding. J. Neurochem. 43:455-465.
17. Wender, M., Adamczewska-Goncerzewicz, Z., Dorszewska, J., Szczech, J., Godlewski, A., Pankrac, J., and Talkowska, D. 1991. Myelin lipids in ischemic stroke. Neuropathol. Pol. 29:87-94.
18. Waxman, S. G., Kocsis, J. D., and Nitta, K. C. 1979. Lysophosphatidyl choline-induced focal demyelination in the rabbit corpus callosum. J. Neurol. Sci. 44:45-53.
19. Sedal, L., Jennings, K. H., Allt, G., Ghabriel, M. N., and Harrison, M. J. 1992. Influence of fatty acid content of lysophosphatidyl choline on its myelinotoxic properties. Eur. Neurol. 32: 4-10.
20. Charlton, C. G. and Way, E. L. 1978. Tremor induced by S-adenosyl-L-methionine: possible relation to L-dopa effects. J. Pharm. Pharmacol. 30:819-820.
21. Crowell, B. G., Benson, R., Shockley, D., and Charlton, C. G. 1993. S-adenosyl-L-methionine decreases motor activity in the rat: similarity to Parkinson's disease-like symptoms. Behav. Neural Biol. 59:186-193.
22. Charlton, C. G. and Mack, J. 1994. Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain. Mol. Neurobiol. 9:149-161.
23. Williams, A. C., Pall, H. S., Steventon, G. B., Green, S., Buttrum, S., Molloy, H., and Waring, R. H. 1993. N-methylation of pyridines and Parkinson's disease. Adv. Neurol. 60:194-196.
24. Aoyama, K., Matsubara, K., Okada, K., Fukushima, S., Shimizu, K., Yamaguchi, S., Uezono, T., Satomi, M., Hayase, N., Ohta, S., Shiono, H., and Kobayashi, S. 2000. N-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: Nicotinamide loading test. J. Neural Transm. 107:985-995.
25. Aoyama, K., Matsubara, K., Kondo, M., Murakawa, Y., Suno, M., Yamashita, K., Yamaguchi, S., and Kobayashi, S. 2001. Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurosci. Lett. 298:78-80.
26. Lamango, S. N., Nesby, R. A., and Charlton, C. G. 2000. Quantification of S-adenosylmethionine-induces tremors: a possible tremor model for Parkinson's disease. Pharmacol. Biochem. Behav. 65:523-529.
27. Lamango, S. N. and Charlton, C. G. 2000. Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats. Pharmacol. Biochem. Behav. 66:841-849.
28. +) increases S-adenosyl-L-methionine dependent phospholipid methylation. Pharmacol. Biochem. Behav. 70: 105-114.
29. Charlton, C. G. 1995. Retrograde neuronal damage caused by lysophosphatidylcholine: role of methylation in neurodegeneration. 25th Annual Society for Neuroscience, Miami, FL.
30. Hornykiewicz, O. 1966. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18:925-964.
31. Mizuno, Y., Sone, N., and Saitoh, T. 1987. Effects of 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenyl-pyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J. Neurochem. 48:1787-1793.
32. Halliwell, B. 1992. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1609-1623.
33. Collins, M. A., Neafsey, E. J., Matsubara, K., Cobuzzi, R. J., Jr., and Rollema, H. 1992. Indole-N-methylated beta-carbolinium ions as potential brain-bioactivates neurotoxins. Brain Res. 570: 154-160.
34. Maruyama, W., Naoi, M., Kasamatsu, T., Hashizume, Y., Takahashi, T., Kohda, K., and Dostert, P. 1997. An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neurochem. 69:322-329.
35. Scholz, J., Bamberg, H., and Moser, A. 1997. N-methyl-norsalsolinol, an endogenous neurotoxin, inhibits tyrosine hydroxylase activity in the rat brain nucleus accumbens in vitro. Neurochem. Int. 31: 845-849.
36. Naoi, M., Mamyama, W., Takahashi, T., Akao, Y., and Nakagawa, Y. 2000. Involvement of endogenous N-methyl(R) salsolinol in Parkinson's disease: Induction of apoptosis and protection by (-) deprenyl. J. Neural Transm. Suppl. 58:111-121.
37. 1 receptor antagonist ligand, in rat striatum. Life Sci. 35: 1885-1893.
38. 3H]-YM-09151-2. Naunyn Schmiedebergs Arch. Pharmacol. 329:333-343.
39. Lowry, C. A., Renner, K. J., and Moore, F. L. 1996. Catecholamines and indoleamines in the central nervous system of a urodele amphibian: a microdissection study with emphasis on the distribution of epinephrine. Brain Behav. Evol. 48:70-93.
40. Scatchard, G. 1949. The Attractions of proteins for small molecules and ions. Ann. NY Acad. Sci. 51:660-672.
41. Hassan, M. N. and Thakar, J. H. 1988. Dopamine receptors in Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 12:173-182.
42. Decamp, E., Wade, T., and Schneider, J. S. 1999. Differential regulation of striatal dopamine D(1) and D(2) receptors in acute and chrome parkinsonian monkeys. Brain Res. 847:134-138.
43. Jenner, P. 2002. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 58:S1-S8.
44. Bonuccelli, U., Colzi, A., and Del Dotto, P. 2002. Pergolide in the treatment of patients with early and advanced Parkinson's disease. Clin. Neuropharmacol. 25:1-10.
45. Gelinas, S. and Martinoli, M. G. 2002. Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells. J Neurosci Res. 70:90-96.
46. McNaught, K. S., Thull, U., Carrupt, P. A., Altomare, C., Cellamare, S., Carotti, A., Testa, B., Jenner, P., and Marsden, C. D. 1995. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Pharmacol. 50:1903-1911.
47. Nicklas, W. J., Vyas, I., and Heikkila, R. E. 1985. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36:2503-2508.
48. Yokota, T. and Hansson, G. K. 1995. Immunological mechanisms in atherosclerosis. J. Intern. Med. 238:479-89.
49. Okita, M., Gaudette, D. C., Mills, G. B., and Holub, B. J. 1997. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients. Int. J. Cancer 71:31-34.
50. Murphy, A. A., Santanam, N., Morales, A. J., and Parthasarathy, S. 1998. Lysophosphatidylcholine, a chemotactic factor for monocytes/ T-lymphocytes is elevated in endometriosis. J. Clin. Endocrinol. Metab. 83:2110-2113.
51. Prokazova, N. V., Zvezdina, N. D., and Korotaeva, A. A. 1998. Effect of lysophosphatidylcholine on transmembrane signal transduction. Biochemistry (Mosc) 63:31-37.
52. Masamune, A., Sakai, Y., Satoh, A., Fujita, M., Yoshida, M., and Shimosegawa, T. 2001. Lysophosphatidylcholine induces apoptosis in AR42J cells. Pancreas 22:75-83.
53. Takahashi, M., Okazaki, H., Ogata, Y., Takeuchi, K., Ikeda, U., and Shimada, K. 2002. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis 161:387-394.
54. Kimura, W., Secknus, R., Fischbach, W., and Mossner, J. 1993. Role of phospholipase A2 in pancreatic acinar cell damage and possibilities of inhibition: Studies with isolated rat pancreatic acini. Pancreas 8:70-79.
55. Hsieh, C. C., Yen, M. H., Liu, H. W., and Lau, Y. T. 2000. Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: In comparison with oxidized LDL. Atherosclerosis 151:481-491.
56. Takeshita, S., Inoue, N., Gao, D., Rikitake, Y., Kawashima, S., Tawa, R., Sakurai, H., and Yokoyama, M. 2000. Lysophosphatidylcholine enhances superoxide anions production via endothelial NADH/NADPH oxidase. J. Atheroscler. Thromb. 7:238-246.
57. Dousset, V., Brochet, B., Vital, A., Gross, C., Benazzouz, A., Boulleme A., Bidabe, A. M., Gin, A. M., and Caille, J. M. 1995. Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. AJNR Am. J. Neuroradiol. 16:225-231.
58. Kabarowski, J. H., Zhu, K., Le, L. Q., Witte, O. N., and Xu, Y. 2001. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 293:702-705.
59. Switzer, S. and Eder, H. A. 1965. Transport of lysolecithin by albumin in human and rat plasma. J. Lipid Res. 6:506-511.
60. Portman, O. W. and Alexander, M. 1969. Lysophosphatidylcholine concentrations and metabolism in aortic intima plus inner media: Effect of nutritionally induced atherosclerosis. J. Lipid Res. 10:158-165.
61. Carson, M. J. and Lo, D. 2001. Immunology. The push-me pull-you of T cell activation. Science 293:618-619.